ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
SYDNEY, Australia, Aug. 29 (Korea Bizwire) — Clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the U.S. Department of Defense (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations. The company also [...]










